Form 4: Terns Pharmaceuticals Director Reports Option Cancellation

Director David A. Fellows reports the cancellation of stock options following the acquisition of Terns Pharmaceuticals by Merck.

Summary

• Director David A. Fellows filed a Form 4 reporting the cancellation of various stock options.
• The cancellation occurred on May 5, 2026, as a result of the merger between Terns Pharmaceuticals and Merck Sharp & Dohme LLC.
• A total of 221,136 options with varying exercise prices ranging from $1.82 to $34.60 were cancelled.
• These options were converted into the right to receive the excess of the $53.00 per share merger consideration over the respective exercise prices.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the completion of a previously announced merger.

Positives

• The merger consideration of $53.00 per share represents a significant liquidity event for shareholders and option holders.

Negatives

• The company is no longer an independent publicly traded entity following the completion of the merger.

Risks

• The company has been acquired, effectively ending its status as a standalone public entity.

Future Outlook

The company has been acquired by Merck; therefore, no further independent forward-looking guidance is provided.

Management Comments

• The options were cancelled and converted into the right to receive the excess of the Merger Consideration over the per share exercise price pursuant to the Merger Agreement.

Industry Context

StockSavvy.ai notes that this filing confirms the finalization of the acquisition of Terns Pharmaceuticals by Merck, a common trend in the biopharmaceutical sector where large-cap firms acquire smaller innovators to bolster their clinical pipelines.

Comparison to Industry Standards

• The acquisition price of $53.00 per share is consistent with standard premium-based buyouts in the biotech sector.
• The conversion of unvested and vested options into cash upon a change of control is standard practice in merger agreements.

Stakeholder Impact

• Shareholders receive $53.00 per share in cash.
• Option holders receive cash payouts based on the spread between the merger price and their exercise price.

Next Steps

• Final delisting of Terns Pharmaceuticals common stock from public exchanges.

Key Dates

Keywords

Terns Pharmaceuticals, Merck, Merger, Acquisition, Form 4, Insider Transaction, Stock Options